Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis

Alessandro Ble, Marta Mosca, Giorgio Di Loreto, Angelo Guglielmotti, Giuseppe Biondi, Stefano Bombardieri, Giuseppe Remuzzi, Piero Ruggenenti

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background/Aims: To test the role of chemokine C-C motif ligand 2 (CCL2) in the pathogenesis of lupus nephritis (LN), we evaluated the effects of CCL2 inhibition by bindarit therapy in patients with systemic lupus and active renal disease. Methods: In this proof-of-concept, prospective, randomized, double-blind clinical study, 22 subjects with acute LN were assigned on a 1:1 ratio to 24-week treatment with bindarit (1,200 mg/day) or matching placebo. All subjects were on the same standardized steroid background therapy. Urinary CCL2, urinary albumin excretion (UAE), estimated glomerular filtration rate, time to remission and time to relapse of LN were compared between groups. Results: Urinary CCL2 significantly decreased during bindarit therapy (p = 0.008 vs. baseline) with a reduction that approximated 50% at study end. CCL2 reduction was paralleled by a persistent reduction in UAE that averaged 80% vs. baseline and approximated 90% at study end. Renal function recovery was similar and no difference was found in terms of time to remission and time to relapse of LN between treatment arms. Treatment was safe and well tolerated in all patients. Conclusion: In lupus subjects with active nephritis, bindarit significantly reduced albuminuria and urinary CCL2 levels. This study provides the background for longer trials to test renoprotective effect of CCL2 inhibition in LN.

Original languageEnglish
Pages (from-to)367-372
Number of pages6
JournalAmerican Journal of Nephrology
Volume34
Issue number4
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Lupus Nephritis
Chemokine CCL2
Ligands
Albumins
Therapeutics
Kidney
Recurrence
Albuminuria
Nephritis
Recovery of Function
Glomerular Filtration Rate
Double-Blind Method
Steroids
Placebos
bindarit

Keywords

  • Albuminuria
  • Bindarit
  • Lupus nephritis
  • Monocyte chemoattractant protein-1
  • Urinary albumin excretion

ASJC Scopus subject areas

  • Nephrology

Cite this

Ble, A., Mosca, M., Di Loreto, G., Guglielmotti, A., Biondi, G., Bombardieri, S., ... Ruggenenti, P. (2011). Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. American Journal of Nephrology, 34(4), 367-372. https://doi.org/10.1159/000330685

Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. / Ble, Alessandro; Mosca, Marta; Di Loreto, Giorgio; Guglielmotti, Angelo; Biondi, Giuseppe; Bombardieri, Stefano; Remuzzi, Giuseppe; Ruggenenti, Piero.

In: American Journal of Nephrology, Vol. 34, No. 4, 10.2011, p. 367-372.

Research output: Contribution to journalArticle

Ble, A, Mosca, M, Di Loreto, G, Guglielmotti, A, Biondi, G, Bombardieri, S, Remuzzi, G & Ruggenenti, P 2011, 'Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis', American Journal of Nephrology, vol. 34, no. 4, pp. 367-372. https://doi.org/10.1159/000330685
Ble, Alessandro ; Mosca, Marta ; Di Loreto, Giorgio ; Guglielmotti, Angelo ; Biondi, Giuseppe ; Bombardieri, Stefano ; Remuzzi, Giuseppe ; Ruggenenti, Piero. / Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. In: American Journal of Nephrology. 2011 ; Vol. 34, No. 4. pp. 367-372.
@article{a56606de44bd4683bcbbf28fb732f1b8,
title = "Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis",
abstract = "Background/Aims: To test the role of chemokine C-C motif ligand 2 (CCL2) in the pathogenesis of lupus nephritis (LN), we evaluated the effects of CCL2 inhibition by bindarit therapy in patients with systemic lupus and active renal disease. Methods: In this proof-of-concept, prospective, randomized, double-blind clinical study, 22 subjects with acute LN were assigned on a 1:1 ratio to 24-week treatment with bindarit (1,200 mg/day) or matching placebo. All subjects were on the same standardized steroid background therapy. Urinary CCL2, urinary albumin excretion (UAE), estimated glomerular filtration rate, time to remission and time to relapse of LN were compared between groups. Results: Urinary CCL2 significantly decreased during bindarit therapy (p = 0.008 vs. baseline) with a reduction that approximated 50{\%} at study end. CCL2 reduction was paralleled by a persistent reduction in UAE that averaged 80{\%} vs. baseline and approximated 90{\%} at study end. Renal function recovery was similar and no difference was found in terms of time to remission and time to relapse of LN between treatment arms. Treatment was safe and well tolerated in all patients. Conclusion: In lupus subjects with active nephritis, bindarit significantly reduced albuminuria and urinary CCL2 levels. This study provides the background for longer trials to test renoprotective effect of CCL2 inhibition in LN.",
keywords = "Albuminuria, Bindarit, Lupus nephritis, Monocyte chemoattractant protein-1, Urinary albumin excretion",
author = "Alessandro Ble and Marta Mosca and {Di Loreto}, Giorgio and Angelo Guglielmotti and Giuseppe Biondi and Stefano Bombardieri and Giuseppe Remuzzi and Piero Ruggenenti",
year = "2011",
month = "10",
doi = "10.1159/000330685",
language = "English",
volume = "34",
pages = "367--372",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis

AU - Ble, Alessandro

AU - Mosca, Marta

AU - Di Loreto, Giorgio

AU - Guglielmotti, Angelo

AU - Biondi, Giuseppe

AU - Bombardieri, Stefano

AU - Remuzzi, Giuseppe

AU - Ruggenenti, Piero

PY - 2011/10

Y1 - 2011/10

N2 - Background/Aims: To test the role of chemokine C-C motif ligand 2 (CCL2) in the pathogenesis of lupus nephritis (LN), we evaluated the effects of CCL2 inhibition by bindarit therapy in patients with systemic lupus and active renal disease. Methods: In this proof-of-concept, prospective, randomized, double-blind clinical study, 22 subjects with acute LN were assigned on a 1:1 ratio to 24-week treatment with bindarit (1,200 mg/day) or matching placebo. All subjects were on the same standardized steroid background therapy. Urinary CCL2, urinary albumin excretion (UAE), estimated glomerular filtration rate, time to remission and time to relapse of LN were compared between groups. Results: Urinary CCL2 significantly decreased during bindarit therapy (p = 0.008 vs. baseline) with a reduction that approximated 50% at study end. CCL2 reduction was paralleled by a persistent reduction in UAE that averaged 80% vs. baseline and approximated 90% at study end. Renal function recovery was similar and no difference was found in terms of time to remission and time to relapse of LN between treatment arms. Treatment was safe and well tolerated in all patients. Conclusion: In lupus subjects with active nephritis, bindarit significantly reduced albuminuria and urinary CCL2 levels. This study provides the background for longer trials to test renoprotective effect of CCL2 inhibition in LN.

AB - Background/Aims: To test the role of chemokine C-C motif ligand 2 (CCL2) in the pathogenesis of lupus nephritis (LN), we evaluated the effects of CCL2 inhibition by bindarit therapy in patients with systemic lupus and active renal disease. Methods: In this proof-of-concept, prospective, randomized, double-blind clinical study, 22 subjects with acute LN were assigned on a 1:1 ratio to 24-week treatment with bindarit (1,200 mg/day) or matching placebo. All subjects were on the same standardized steroid background therapy. Urinary CCL2, urinary albumin excretion (UAE), estimated glomerular filtration rate, time to remission and time to relapse of LN were compared between groups. Results: Urinary CCL2 significantly decreased during bindarit therapy (p = 0.008 vs. baseline) with a reduction that approximated 50% at study end. CCL2 reduction was paralleled by a persistent reduction in UAE that averaged 80% vs. baseline and approximated 90% at study end. Renal function recovery was similar and no difference was found in terms of time to remission and time to relapse of LN between treatment arms. Treatment was safe and well tolerated in all patients. Conclusion: In lupus subjects with active nephritis, bindarit significantly reduced albuminuria and urinary CCL2 levels. This study provides the background for longer trials to test renoprotective effect of CCL2 inhibition in LN.

KW - Albuminuria

KW - Bindarit

KW - Lupus nephritis

KW - Monocyte chemoattractant protein-1

KW - Urinary albumin excretion

UR - http://www.scopus.com/inward/record.url?scp=80052097156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052097156&partnerID=8YFLogxK

U2 - 10.1159/000330685

DO - 10.1159/000330685

M3 - Article

C2 - 21876349

AN - SCOPUS:80052097156

VL - 34

SP - 367

EP - 372

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 4

ER -